Papillomavirus Hpv Testing Market Scope
Diagnostics technology is advancing rapidly. The drivers driving market growth are the rising number of screening programmes and the rising prevalence of chronic diseases, such as vaginal and cervical cancer, worldwide. A laboratory procedure where cells are examined for DNA or RNA from certain HPV strains known to cause cervical cancer. These high-risk HPV variants can also result in malignancies of the anus, vagina, vulva, penis, and oropharynx, among other cancers. An HPV test, also known as primary HPV testing, may be used alone to screen for cervical cancer or in conjunction with a Pap test (called cotesting). The results of some abnormal Pap tests may also warrant an HPV test. Also known as a test for human papillomavirus.
|Unit||Value (USD Million)|
|Key Companies Profiled||Abbott Laboratories (United States), Hologic Inc. (United States), Cepheid Inc. (United States), Seegene Inc. (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (United States), Greiner Bio-One International GmbH (Austria), Enzo Biochem Inc. (United States), Thermo Fisher Scientific Inc. (United States), Takara Bio Inc. (Japan), Agilent Technologies, Inc. (United States), Norgen Biotek Corp. (Canada), DiagCor Bioscience Inc Ltd (China), Hybribio Limited (China) and Zytovision GmbH (Germany)|
The market for the Papillomavirus Hpv Testing is highly competitive and dominated by few key player. The market has a vendor landscape that is extremely competitive. A number of businesses are also taking part in significant mergers and acquisitions as part of crucial plans to increase their market share globally. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Papillomavirus Hpv Testing market throughout the predicted period.
Abbott Laboratories (United States), Hologic Inc. (United States), Cepheid Inc. (United States), Seegene Inc. (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (United States), Greiner Bio-One International GmbH (Austria), Enzo Biochem Inc. (United States), Thermo Fisher Scientific Inc. (United States), Takara Bio Inc. (Japan), Agilent Technologies, Inc. (United States), Norgen Biotek Corp. (Canada), DiagCor Bioscience Inc Ltd (China), Hybribio Limited (China) and Zytovision GmbH (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Becton, Dickinson and Company (United States), Qiagen N.V. (Netherland), Arbor Vita Corporation (United States), Medical & Biological Laboratories Co., Ltd (Japan) and Fujirebio Diagnostics, Inc. (Japan).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
The study have segmented the market of Global Papillomavirus Hpv Testing market by Type , by Application (Cervical Cancer Screening, Vaginal Cancer Screening, Molecular Diagnostics and Research Use) and Region with country level break-up.
On the basis of geography, the market of Papillomavirus Hpv Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.
Market Leaders and their expansionary development strategies
On March 2021, a renowned provider of medical technology, BD (Becton, Dickinson and Company), has announced that the first self-collection claim for HPV screening to comply with the IVD Directive 98/79/EC has received CE marking. The new claim enables labs and facilities to use the BD OnclarityTM HPV Assay on either the BD ViperTM LT or the BD CORTM System to process self-collected samples using a BD diluent tube. The BD CORTM System, introduced last year, is in use all throughout Europe, while the BD ViperTM LT is in use globally
Influencing Trend:The primary factor fuelling the market's expansion is the increase in awareness campaigns by different organisations
Market Growth Drivers:The market is expanding due to an increase in cervical cancer screening programmes and Cervical cancer cases on the rise with an ageing population propelling the factor forward
Challenges:Uncertain reimbursement policies hinder economic progress
Restraints:Human papillomavirus vaccination is the factor hampering the market growth and Lack of skilled workforce restrict the market growth
Opportunities:Technological advancement such as Artificial intelligence creates lucrative growth opportunities for the market and Government programmes and funding will produce attractive market expansion prospects
Key Target AudienceNew Entrants and Investors, Laboratories, Hospitals, Diagnostic Centers, Clinics, Research Institutes, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others